AU2005320349C1 - Antibodies against clostridium difficile toxins and uses thereof - Google Patents

Antibodies against clostridium difficile toxins and uses thereof Download PDF

Info

Publication number
AU2005320349C1
AU2005320349C1 AU2005320349A AU2005320349A AU2005320349C1 AU 2005320349 C1 AU2005320349 C1 AU 2005320349C1 AU 2005320349 A AU2005320349 A AU 2005320349A AU 2005320349 A AU2005320349 A AU 2005320349A AU 2005320349 C1 AU2005320349 C1 AU 2005320349C1
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen binding
toxin
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2005320349A
Other languages
English (en)
Other versions
AU2005320349A1 (en
AU2005320349B2 (en
AU2005320349B8 (en
AU2005320349A8 (en
Inventor
Donna Ambrosino
Gregory J. Babcock
Theresa Broering
Robert Graziano
Hector Javier Hernandez
Israel Lowy
Robert Mandell
Deborah Molrine
William D. Thomas Jr.
Hui-Fen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
University of Massachusetts Amherst
Original Assignee
ER Squibb and Sons LLC
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005320349(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ER Squibb and Sons LLC, University of Massachusetts Amherst filed Critical ER Squibb and Sons LLC
Publication of AU2005320349A1 publication Critical patent/AU2005320349A1/en
Publication of AU2005320349A8 publication Critical patent/AU2005320349A8/en
Publication of AU2005320349B2 publication Critical patent/AU2005320349B2/en
Application granted granted Critical
Publication of AU2005320349B8 publication Critical patent/AU2005320349B8/en
Assigned to MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTS reassignment MEDAREX, L.L.C. Request to Amend Deed and Register Assignors: MEDAREX, INC., UNIVERSITY OF MASSACHUSETTS
Assigned to E. R. SQUIBB & SONS, L.L.C., UNIVERSITY OF MASSACHUSETTS reassignment E. R. SQUIBB & SONS, L.L.C. Request to Amend Deed and Register Assignors: MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTS
Publication of AU2005320349C1 publication Critical patent/AU2005320349C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
AU2005320349A 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof Active 2030-02-04 AU2005320349C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US60/542,357 2004-02-06
US61385404P 2004-09-28 2004-09-28
US60/613,854 2004-09-28
PCT/US2005/003725 WO2006121422A2 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Publications (5)

Publication Number Publication Date
AU2005320349A1 AU2005320349A1 (en) 2006-08-24
AU2005320349A8 AU2005320349A8 (en) 2008-08-07
AU2005320349B2 AU2005320349B2 (en) 2010-04-08
AU2005320349B8 AU2005320349B8 (en) 2010-04-22
AU2005320349C1 true AU2005320349C1 (en) 2019-06-13

Family

ID=36928722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005320349A Active 2030-02-04 AU2005320349C1 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Country Status (28)

Country Link
US (8) US7625559B2 (cg-RX-API-DMAC10.html)
EP (3) EP1766093B1 (cg-RX-API-DMAC10.html)
JP (3) JP4588763B2 (cg-RX-API-DMAC10.html)
KR (3) KR101332994B1 (cg-RX-API-DMAC10.html)
CN (1) CN101014620B (cg-RX-API-DMAC10.html)
AT (1) ATE512986T1 (cg-RX-API-DMAC10.html)
AU (1) AU2005320349C1 (cg-RX-API-DMAC10.html)
BE (1) BE2017C023I2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0507433C1 (cg-RX-API-DMAC10.html)
CA (1) CA2553946C (cg-RX-API-DMAC10.html)
CY (3) CY1111860T1 (cg-RX-API-DMAC10.html)
DK (3) DK2857418T3 (cg-RX-API-DMAC10.html)
ES (3) ES2366626T3 (cg-RX-API-DMAC10.html)
FR (1) FR17C1025I2 (cg-RX-API-DMAC10.html)
HR (1) HRP20110599T1 (cg-RX-API-DMAC10.html)
HU (3) HUE024962T2 (cg-RX-API-DMAC10.html)
LT (2) LT2857418T (cg-RX-API-DMAC10.html)
LU (1) LUC00025I2 (cg-RX-API-DMAC10.html)
MX (1) MXPA06008839A (cg-RX-API-DMAC10.html)
NL (1) NL300881I2 (cg-RX-API-DMAC10.html)
NO (2) NO340300B1 (cg-RX-API-DMAC10.html)
NZ (2) NZ580828A (cg-RX-API-DMAC10.html)
PL (3) PL2270045T3 (cg-RX-API-DMAC10.html)
PT (3) PT1766093E (cg-RX-API-DMAC10.html)
RS (1) RS51908B (cg-RX-API-DMAC10.html)
SI (3) SI1766093T1 (cg-RX-API-DMAC10.html)
WO (1) WO2006121422A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200606516B (cg-RX-API-DMAC10.html)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
MXPA06008839A (es) * 2004-02-06 2008-03-07 Univ Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
AU2005257527B9 (en) * 2004-06-28 2009-03-05 Japan Science And Technology Agency Method of screening toxin-neutralizing peptide, STX2 inhibitory peptide and vero toxin-neutralizing agent
EP1833510A4 (en) * 2004-12-27 2010-02-10 Progenics Pharmaceuticals Neva ORAL ADMINISTRATION ANTITOXIN ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
JP5345532B2 (ja) 2006-08-02 2013-11-20 ヨハネス・グーテンベルク−ウニヴェルジテート・マインツ Ｌｃｔ中毒に対する医薬品
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
EP2423221B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
WO2009154995A2 (en) * 2008-05-27 2009-12-23 Kyowa Hakko Kirin Co., Ltd. Interleukin 10 receptor (il-10r) antibodies and methods of use
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
CA2752815A1 (en) * 2009-02-20 2010-08-26 Health Protection Agency Antibodies to clostridium difficile toxins
JP5591332B2 (ja) * 2009-07-27 2014-09-17 バイオディクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 試料中における変異したｃ．ディフィシル菌株を検出および同定するための方法
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
JP5965389B2 (ja) * 2010-04-15 2016-08-03 プロゲニクス ファーマシューティカルズ インコーポレーテッドＰｒｏｇｅｎｉｃｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． クロストリジウム・ディフィシル関連感染症および疾患を治療するための抗体
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
MX350126B (es) 2010-09-03 2017-08-28 Valneva Austria Gmbh Polipéptido aislado de las proteínas de la toxina a y la toxina b de c. difficile y usos del mismo.
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
CA2815888C (en) * 2010-10-25 2020-06-30 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US20140127215A1 (en) * 2010-12-29 2014-05-08 Cangene Corporation Clostridium difficile antigens
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
HUE047085T2 (hu) 2011-04-22 2020-04-28 Wyeth Llc Clostridium difficile mutáns toxinjához kapcsolódó készítmények és eljárásai
CN104203287B (zh) * 2011-07-12 2017-07-14 费城健康及教育公司，d/b/a,德雷克塞尔大学医学院 新型艰难梭菌dna疫苗
US9505847B2 (en) 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
HK1199463A1 (en) * 2011-09-16 2015-07-03 Ucb医药有限公司 Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
ES2704069T3 (es) 2011-12-08 2019-03-14 Glaxosmithkline Biologicals Sa Vacuna basada en toxinas de Clostridium difficile
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
SG10201610123UA (en) * 2012-03-02 2017-01-27 Regeneron Pharma Human antibodies to clostridium difficile toxins
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2921502A4 (en) * 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
EP2925362A4 (en) * 2012-11-28 2016-07-20 Cnj Holdings Inc ANTIBODIES DIRECTED AGAINST CLOSTRIDIUM DIFFICILE
EP4079760A3 (en) * 2013-03-15 2023-01-25 Sanofi Pasteur Inc. Antibodies against clostridium difficile toxins and methods of using the same
EP2986316B1 (en) * 2013-04-19 2023-01-25 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
WO2015123777A1 (en) 2014-02-19 2015-08-27 Cangene Corporation Methods of modulating an immune response
WO2015157629A2 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
WO2015184454A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Clostridium difficile culture medium
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
CA2976976C (en) * 2015-02-19 2023-02-28 Immune Biosolutions Inc. Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
WO2016156475A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
EA202091898A1 (ru) 2015-12-15 2021-06-22 Джилид Сайэнс, Инк. Антитела, нейтрализующие вирус иммунодефицита человека
EP3448987A4 (en) * 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
AU2018290228B2 (en) 2017-06-21 2021-07-01 Gilead Sciences, Inc. Multispecific antibodies that target HIV gp120 and CD3
CA3097748A1 (en) * 2018-04-19 2019-10-24 First Light Biosciences, Inc. Detection of targets
AU2019353145B2 (en) 2018-10-04 2025-12-04 First Light Diagnostics, Inc. Microbial analysis without cell purification
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
CN112812189B (zh) * 2020-11-30 2022-05-17 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN116239683B (zh) * 2023-02-15 2024-12-27 兰州生物制品研究所有限责任公司 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用
WO2025140549A1 (en) * 2023-12-29 2025-07-03 Etinpro (Beijing) Co. Ltd. Immune stimulating anti-hbsag antibody conjugates, pharmaceutical compositions, and therapeutic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012971A2 (de) * 1997-09-10 1999-03-18 Von Eichel Streiber Christoph Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine
WO2001092340A2 (en) * 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) * 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH08503121A (ja) * 1991-12-10 1996-04-09 デイナ・フアーバー・キヤンサー・インステイテユート 中和反応性ヒト抗−ｇｐ１２０組換え抗体、それをコードするｄｎａおよびその使用
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE69535530D1 (de) 1994-10-24 2007-08-16 Ophidian Pharm Inc Impfstoff und Antitoxine zur Behandlung und Vorbeugung von C. Difficile Krankheiten
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
WO1999020304A1 (en) * 1997-10-20 1999-04-29 Oravax, Inc. Passive immunization against clostridium difficile disease
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
KR20020047132A (ko) 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI327597B (en) * 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
NZ534687A (en) * 2002-01-28 2007-10-26 Medarex Inc Human monoclonal antibodies to prostate specific membrane antigen (PSMA) seq id 54
ATE510561T1 (de) * 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
EP1490405B1 (en) * 2002-03-21 2007-08-22 Eli Lilly And Company ANTAGONISTIC ANTI-hFAS LIGAND HUMAN ANTIBODIES AND FRAGMENTS THEREOF
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
JP2007527193A (ja) 2002-12-10 2007-09-27 アンドキューブ ソシエタ パー アクシオン シンプリフィー ケモカインに対する核受容体としてのｔｈａｐタンパク質と、転写調節、細胞増殖、および細胞分化におけるその役割
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
HUE025328T2 (en) * 2003-12-10 2016-03-29 Squibb & Sons Llc IP-10 antibodies and their use
MXPA06008839A (es) 2004-02-06 2008-03-07 Univ Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012971A2 (de) * 1997-09-10 1999-03-18 Von Eichel Streiber Christoph Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine
WO2001092340A2 (en) * 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORTHIER, G. et al. 1991 INFECTION AND IMMUNITY, vol. 59, p.1192-1195 *
FREY, S.M. et al. 1992 INFECTION AND IMMUNITY. vol. 60, pages 2488-2492 *
KINK, J.A. et al. 1998 INFECTION AND IMMUNITY, vol. 66, p. 2018-2025 *
SALCEDO, J. et al. 1997 GUT, vol. 41, p. 366-370 *

Also Published As

Publication number Publication date
AU2005320349A1 (en) 2006-08-24
PT2270045E (pt) 2015-04-08
KR20120003017A (ko) 2012-01-09
JP2007533330A (ja) 2007-11-22
US20140120614A1 (en) 2014-05-01
US8609111B2 (en) 2013-12-17
HUE024962T2 (en) 2016-02-29
US20100233181A1 (en) 2010-09-16
ZA200606516B (en) 2011-01-26
JP2011019516A (ja) 2011-02-03
BRPI0507433C1 (pt) 2021-05-25
CN101014620A (zh) 2007-08-08
BRPI0507433B8 (pt) 2018-04-10
CY2017022I2 (el) 2017-11-14
BRPI0507433A (pt) 2007-07-03
HRP20110599T1 (hr) 2011-10-31
HK1102287A1 (en) 2007-11-09
HUS1700028I1 (hu) 2017-07-28
KR20120083534A (ko) 2012-07-25
ATE512986T1 (de) 2011-07-15
HUE034552T2 (en) 2018-02-28
PL1766093T3 (pl) 2011-11-30
CA2553946C (en) 2019-02-26
CA2553946A1 (en) 2005-08-06
JP4588763B2 (ja) 2010-12-01
EP2857418B1 (en) 2017-07-26
EP1766093A2 (en) 2007-03-28
LUC00025I2 (cg-RX-API-DMAC10.html) 2017-09-08
JP2013153750A (ja) 2013-08-15
DK2270045T3 (en) 2015-04-07
LTC2270045I2 (lt) 2019-12-10
KR101332927B1 (ko) 2013-11-26
US20180208643A1 (en) 2018-07-26
PT1766093E (pt) 2011-08-24
LTPA2017022I1 (lt) 2017-09-11
CY2017022I1 (el) 2017-11-14
EP2270045B8 (en) 2015-02-25
JP5717300B2 (ja) 2015-05-13
SI2270045T1 (sl) 2015-06-30
CY1119416T1 (el) 2018-03-07
BRPI0507433B1 (pt) 2018-03-20
WO2006121422A3 (en) 2007-03-15
US20100233182A1 (en) 2010-09-16
EP2857418A1 (en) 2015-04-08
ES2643760T3 (es) 2017-11-24
FR17C1025I1 (fr) 2017-08-09
NO2017032I1 (no) 2017-07-07
US7625559B2 (en) 2009-12-01
MXPA06008839A (es) 2008-03-07
CN101014620B (zh) 2012-05-09
WO2006121422A2 (en) 2006-11-16
DK1766093T3 (da) 2011-10-03
AU2005320349B2 (en) 2010-04-08
NZ548821A (en) 2009-12-24
EP2270045A1 (en) 2011-01-05
PL2270045T3 (pl) 2015-06-30
NL300881I2 (nl) 2024-07-16
PT2857418T (pt) 2017-10-20
SI2857418T1 (en) 2018-01-31
BE2017C023I2 (cg-RX-API-DMAC10.html) 2024-08-08
AU2005320349B8 (en) 2010-04-22
EP1766093B1 (en) 2011-06-15
HK1152048A1 (en) 2012-02-17
US20210269511A1 (en) 2021-09-02
DK2857418T3 (en) 2017-10-23
US20050287150A1 (en) 2005-12-29
ES2533492T3 (es) 2015-04-10
KR101332994B1 (ko) 2013-11-26
US8257709B2 (en) 2012-09-04
LT2857418T (lt) 2017-09-25
JP5319622B2 (ja) 2013-10-16
US9217029B2 (en) 2015-12-22
PL2857418T3 (pl) 2017-10-31
US8236311B2 (en) 2012-08-07
US20120288508A1 (en) 2012-11-15
NO20063767L (no) 2006-10-02
US20160152694A1 (en) 2016-06-02
HK1208873A1 (en) 2016-03-18
AU2005320349A8 (en) 2008-08-07
WO2006121422A8 (en) 2007-04-26
EP2270045B1 (en) 2014-12-31
NO340300B1 (no) 2017-03-27
RS51908B (sr) 2012-02-29
LUC00025I1 (cg-RX-API-DMAC10.html) 2017-07-06
CY1111860T1 (el) 2015-11-04
SI1766093T1 (sl) 2011-12-30
KR20070050863A (ko) 2007-05-16
FR17C1025I2 (fr) 2019-11-15
NZ580828A (en) 2011-09-30
ES2366626T3 (es) 2011-10-24

Similar Documents

Publication Publication Date Title
AU2005320349C1 (en) Antibodies against clostridium difficile toxins and uses thereof
HK1208873B (en) Antibodies against clostridium difficile toxins and uses thereof
HK1152048B (en) Antibodies against clostridium difficile toxins and uses thereof
HK1102287B (en) Antibodies against clostridium difficile toxins and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 20, NO 32, PAGE(S) 3170 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

Free format text: IN VOL 20, NO 32, PAGE(S) 3140 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

TH Corrigenda

Free format text: IN VOL 20, NO 32, PAGE(S) 3170 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

Free format text: IN VOL 20, NO 32, PAGE(S) 3140 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

TH Corrigenda

Free format text: IN VOL 24, NO 14, PAGE(S) 1619 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAMES UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID (72) ADD THE CO-INVENTOR GRAZIANO, ROBERT

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY 2010.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 OCT 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY AND 16 JUL 2010

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 OCT

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ZINPLAVA BEZLOTOXUMAB (RCH)

Filing date: 20171113

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 OCT 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 15 OCT 2018

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ZINPLAVA BEZLOTOXUMAB (RCH)

Filing date: 20171113

Extension date: 20300204